• Bionano Genomics Inc BNGO.OQ BNGO.O is expected to show a fall in quarterly revenue when it reports results on May 6 (estimated) for the period ending March 31 2025

• The San Diego California-based company is expected to report a 28.9% decrease in revenue to $6.233 million from $8.77 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.The company's guidance on March 31 2025, for the period ended March 31, was for revenue between $6.20 million and $6.30 million.

• ​LSEG's mean analyst estimate for Bionano Genomics Inc is for a loss of $3.02 per share.

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts had risen by about 25.0% in the last three months. ​

• Wall Street's median 12-month price target for Bionano Genomics Inc is $7.00​, above​ its last closing price of $4.00. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated May 2 at 11:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)